Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Eli Lilly and Company
Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
April 4th, 2009
Today Eli Lilly and Company (NYSE:LLY) announced its support for the Pathway for Biosimilars Act. The U.S. has a 25-year history of success with laws promoting the discovery of new, chemical-based medicines and providing an abbreviated approval process under which generic versions of those new medicines can to come to market. But Congress has yet to take that step with the most advanced new medicines, called biological drugs or simply "biologics." Lilly said the Pathway for Biosimilars Act, reintroduced in the 111th Congress by Reps. Anna Eshoo (D-Calif.), Jay Inslee (D-Wash.) and Joe Barton (R-Texas), would successfully create a pathway that carefully weighs the needs...
Source: Law & Health Weekly (2009-04-04)
|
